ISSN: 2754-6659

Journal of Artificial Intelligence & Cloud Computing

SCIENTIFIC Research and Community

Review Article

Open Access

Navigating towards AI success: A Comprehensive Roadmap for Implementation

Ivo ten Voorde

AI Project Manager and Consultant, Netherlands

ABSTRACT

Artificial Intelligence (AI) is revolutionizing the pharmaceutical industry, enhancing efficiency, safety, and compliance. In this article, we delve into the steps necessary for successful AI implementation within pharmaceutical logistics. I'll provide my own experience, real life cases, links to scientific articles, and adhere to guidelines from respected regulatory bodies. By following my approach ensures compliance with Good Manufacturing Practices (GMP), Good Distribution Practices (GDP), and various ISO standards and will aid in a successful implementation.

***Corresponding author**

Ivo ten Voorde, AI Project Manager and Consultant, Netherlands.

Received: April 04, 2024; **Accepted:** April 10, 2024; **Published:** April 29, 2024

Introduction

Implementing a successful Artificial Intelligence (AI) within your pharmaceutical manufacturing and/or logistics organisation is not just about integrating cutting-edge technology-it's about redefining how quality management aligns with the rigorous standards like Good Manufacturing Practices (GMP), Good Distribution Practices (GDP),various ISO certifications and country specific regulatory requirements [1-8]. Your approach must ensure that you are embracing technological innovation, while in the meantime ensuring compliance with regulatory requirements. In this article, I'll go into the outline of a comprehensive, step-by-step manual to successfully implement AI within pharmaceutical organisation and logistics and dive into my own experience and research from others.

Initial Idea: Identifying Opportunities for AI Implementation

Your objective here is to identify areas within your pharmaceutical manufacturing and/or logistics operations where AI can bring significant benefits, such as enhancing efficiency, optimizing supply chain management, improving predictive maintenance, and ensuring regulatory compliance.

The steps below can be followed:

Establishing a Dedicated Cross-Functional AI Implementation Team

Begin with assembling a dedicated team that includes a project manager, quality manager(s), data scientists (QA/QC), regulatory affairs specialists, and key operational staff. This diversity ensures a well-rounded approach to integrating AI technologies, focusing on operational excellence and regulatory compliance. If possible add an AI expert as well, if you have this internally available.

Gap Analysis

Conduct a thorough assessment of current processes, challenges, and opportunities within the organization's manufacturing and logistics operations. Then ensure you identify the areas AI can or will be helpful to assist and ensure you have your **scope** and limitations clear.

Tip from myside: use a patient journey map on your service/ product and this visualisation will help you to identify where and in which stages AI could help (Research, testing trials, manufacturing, diagnostic, quality control, administrative tasks, analytics and so on) [9,10].

Data Strategy

Have a clear strategy what you want to improve and use your scope and limitations as starting point. AI can help in many fields but ensure you focus on key-areas identified in the GAP analyses and I'll mention here some areas where AI can give you quick-win like in:

- Data analytics analysing and cleaning up data (operations / research / clinical trials / testing) [11,12]
- Linking datasets (anonymous patients data) and simulate results to identify patterns and or predict (negative) side effects (end user care / diagnostic aid / operational excellence) [13-15]
- Quality control (imaging / anti-fraud / deviations avoidance) [16,17]
- Predictive maintenance (operations) [18,19]
- Automation of inventory management (operations / logistics) [20]
- Risk management (operations / logistics / end user care / diagnostics) [21,22]
- Aiding in administrative tasks (scheduling meetings, translations etc.) [23,24]

With your scope clear and you've identified which areas AI could improve your organisation and can start consulting the stakeholders.

Stakeholder Consultation
Engage key stakeholders and ensure you do include the (end) users and impacted departments. This does mean you should not forget to ask feedback from the workers, who'll be impacted by the change. Include your manufacturing- & logistics departments, supply chain experts, regulatory compliance officers, end-users (doctors/nurses/operators) and your IT professionals. Ensure you have a good understanding of their pain points and potential areas for AI intervention. With their feedback combined this in what I call your **Package of Demands (PoD)**. This PoD includes the following important information and is the foundation of your AI. It includes your AI vision, objectives and defences clearly on the following topics:

- The quality and availability of the data the AI will be trained on [25,26]
- Transparency and quality controls of the AI (deviations avoidance and regulatory compliance, security issues) [27-31]
- Governance and monitoring (evaluation) controls [32]
- Scope and which legal frameworks to include (GMP/ GDP/21CRF-11/ISO)
- Budget & Cost effectiveness, is AI nice to have but too expensive, cost saving and / or increase patient safety by improving quality of product/service? [33]
- Training and increase the awareness of the users of the AI, because if you enter "bad" prompts, you can't expect a good reply.
- Avoiding biases and form a transparent ethical framework [34-36]
- Patients approval and privacy concerns [37,38]
- Prioritize AI use cases based on their potential impact, feasibility, and alignment with organizational goals and applicable regulatory requirements.

Market Research
Now with your Package of Demands you can sent out a tender and do market research of what is available on the market of AI solutions. Explore off the shelve AI applications and solutions tailored made to the need of your organisation and related industry.

Even when third parties are sending in their offers, you yourself should consider looking into case studies, whitepapers, and industry reports from respectable peer review studies and sources. It can save a lot of time and if known pitfalls can be avoided, you should do so.

As an alternative solution you can also opt to build an AI yourself – however this is a whole complete new undertaking. Your organisation should have at least the personal available for this (dedicated), and need to have (AI) experts inhouse already. If not, my advice is strongly to **NOT** chose this option.

Selecting the Right AI Solution: Ensuring Effectiveness and Compliance
Objective: Choose AI solutions that meet the specific needs of the organization while ensuring regulatory compliance and mitigating known pitfall like biases. The following steps can be followed:

Requirements Definition
Clearly define the functional requirements, technical specifications, and regulatory constraints for the desired AI solution. Simply put, link your (medical) context and limitations in which AI will aid your organisation.

Vendor Evaluation
Evaluate AI vendors based on their experience in the pharmaceutical or relevant industry, track record of successful implementations, compliance with relevant regulations (e.g., FDA, EMA), and approach to bias mitigation.

Be aware that regulators will demand you have your risk mitigation and profiles in order no matter what solution you choose. The "AI maturity" can be seen in these forms and amount of risk and impact varies:

- **Experimental: like the name suggest:** it's a new solution and is excellent for testing and for research. Not feasible to be implemented directly to wider public/patients
- **Newly Introduced:** new in your market (country), AI solution where there is some clinical evidence and proof of concept. The results obtained are from other countries, but not introduced or used yet in the country of your organisation.
- **AI - Version 2 or Higher:** Used by many different countries already or has substantial evidence and trails completed and results are published and available. Even other organisations and/or your competitors locally are using this AI solution or are in process of doing so.
- **Tender Execution:** Let the market decide if they have the right solution for your organisational wishes and tailor make a solution.
- **Own Creation:** Alternatively as mentioned before, you can invent your own AI model, but this is option is not my personal recommendation.

Proof of Concept (PoC)
Conduct a PoC with your selected vendor(s) to assess the feasibility and performance of their AI solutions in real-world scenarios. Ensure that PoC includes rigorous testing for bias and fairness and ensure compliance and mitigate your risks [39,40].

Compliance Review
Collaborate with legal and regulatory experts to ensure that the selected AI solution complies with data privacy regulations (e.g., GDPR), industry standards (e.g., Good Distribution Practice), and ethical guidelines (e.g., IEEE AI Ethics Initiative) [41].

Testing and Implementation: Deploying AI Solutions Safely and Effectively
Objective: Deploy AI solutions in a controlled manner, ensuring minimal disruption to operations while maximizing benefits, with the following steps

Data Preparation
Cleanse and preprocess data to ensure accuracy, completeness, and relevance for AI model training. Use techniques such as data anonymization and de-identification to protect sensitive information. You don't want to have issue with this later on and especially in markets like EU and US privacy is an important matter [42].
Also, don't forget that AI is only as smart as good as the data you train/feed it, if you put
"**garbage in your output will be garbage as well**" [43-46].

Model Development
Develop AI models using appropriate algorithms (e.g., machine learning, deep learning) and techniques (e.g., supervised learning, reinforcement learning) based on the nature of the problem and available data.

Testing and Validation
Conduct thorough testing and validation of AI models using diverse datasets and realistic scenarios. Evaluate model performance metrics such as accuracy, precision, recall, and F1-score and follow available guidelines from inspection institutes like the FDA [47,48].

Pilot Deployment
Roll out the AI solution in a pilot environment or limited production setting to assess its performance, scalability, and user acceptance. Collect feedback from end-users and stakeholders for iterative improvement. Make sure your evaluate and do correction, before the AI model goes full scale.

Full-Scale Deployment
Gradually scale up the deployment of AI solution across the organization's logistics and airfreight operations, ensuring proper training, documentation, and support for end-users.

Don't forget to train the staff on the new features and changes and use the feedback and questions as learning opportunities to tweak and improve your AI model.

Follow-up, Monitoring and Control Mechanism
Objective: Establish mechanisms for ongoing monitoring, evaluation, and refinement of deployed AI solutions to ensure effectiveness, compliance, and fairness. The following items can be used:

Performance Monitoring
Implement monitoring tools and dashboards to track the performance of AI models in real-time, including key metrics such as accuracy, latency, and resource utilization [49].

Feedback Loop
Collect and encourage feedback from end-users, domain experts, and stakeholders to identify possible issues, challenges, and opportunities for improvement. Incorporating a feedback culture into iterative model updates and refinements. Additionally ensure a minimum of a yearly mock recalls or simulation deviations to test if the AI is still doing what it supposed to do.

Bias Detection and Mitigation
Continuously monitor AI models for biases and unfair outcomes, leveraging techniques such as fairness-aware algorithms, bias detection frameworks, and diverse training data. Also to ensure the AI links relevant criteria and avoid the trouble with early models, where Wolfs were misidentified or the big disaster of Google's launch with Gemini image creator and Amazon recruitment process fail [50-52].

Compliance Audits
Conduct periodic audits and reviews to ensure that deployed AI solutions remain compliant with regulatory requirements, industry standards, and ethical guidelines.

Create with AI as aid towards a culture of always doing it well, also when no one is looking. Because patient safety must be of utmost importance at all times.

Training and Education
Provide ongoing training and education to employees about AI technologies, best practices, and ethical considerations. Foster a culture of transparency, accountability, and responsible AI usage within the organization.

Conclusion
Please go ahead and use my plan as a comprehensive framework for a start of AI implementation.

I've covered some critical key stages starting from idea to deployment and monitoring.

Emphasizing on the importance of key areas like bias mitigation, and continuous improvement, which are crucial considerations in highly regulated industries. The successful implementation of AI within pharmaceutical and/or logistical organisations hinges on a strategic approach that balances innovation with regulatory compliance. By following the outlined steps and learning from real-life cases, organizations can harness the power of AI to enhance operational efficiency, improve product distribution and improve the ultimate goal: **Patient Safety**.

References
1. Yang Judy X, Li Lily D, Rasul Mohammad (2021) Warehouse Management Models Using Artificial Intelligence Technology with Application at Receiving Stage - A Review. International Journal of Machine Learning and Computing 11: 242-249.
2. Ashley Welch (2023) Artificial intelligence is helping revolutionize healthcare as we know it. Johnson & Johnson https://www.jnj.com/innovation/artificial-intelligence-in-healthcare.
3. Iakovlev Igor, Kremleva Elmira, Guzanov Roman (2023) Enterprise automation using artificial intelligence: Methods, technologies and prospects. E3S Web of Conferences 460. 10.1051/e3sconf/202346004007.
4. Good manufacturing practice. European Medicines Agency https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice.
5. Good distribution practice. European Medicines Agency https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/compliance-post-authorisation/good-distribution-practice.
6. ISO/IEC 42001:2023 Information technology-Artificial Intelligence-Management system. ISO https://www.iso.org/standard/81230.html.
7. ISO/IEC 23894:2023 Information technology-Artificial intelligence-Guidance on risk management https://www.iso.org/standard/77304.html.
8. ISO/IEC 25059:2023 Software engineering-Systems and software Quality Requirements and Evaluation (SQuaRE)-Quality model for AI systems https://www.iso.org/standard/80655.html.
9. Amanda L Joseph, Helen M, Yuri Q (2023) Exploring Patient Journey Mapping and the Learning Health System: Scoping Review. JMIR Hum Factors 10: e43966.
10. Doris Wójcicka (2015) 10 Most interesting examples of Customer Journey Maps. UXeria https://uxeria.com/en/10-most-interesting-examples-of-customer-journey-maps/.
11. Chui KT, Lytras MD, Visvizi, A, Sarirete A (2021) An overview of artificial intelligence and big data analytics for smart healthcare: requirements, applications, and challenges. Artificial intelligence and big data analytics for smart healthcare 243-254.

12. Khan ZF, Alotaibi SR (2020) Applications of artificial intelligence and big data analytics in m-health: a healthcare system perspective. Journal of healthcare engineering 1-15.
13. Harmon SA, Sanford TH, Xu S, Turkbey EB, Roth H, et al. (2020) Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets. Nature communications 11: 4080.
14. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A (2019) Artificial intelligence in digital pathology-new tools for diagnosis and precision oncology. Nature reviews Clinical oncology 16: 703-715.
15. Kuchana M, Srivastava A, Das R, Mathew J, Mishra A, et al. (2021) AI aiding in diagnosing, tracking recovery of COVID-19 using deep learning on Chest CT scans. Multimedia tools and applications 80: 9161-9175.
16. Ferdosi BJ, Sakib MA, Islam MS, Dhar J (2021) Identifying counterfeit medicine in bangladesh using deep learning. In International Conference on Human-Centered Intelligent Systems 46-55.
17. Moglianetti M, Pedone D, Morerio P, Scarsi A, Donati P, et al. (2022) Nanocatalyst-Enabled Physically Unclonable Functions as Smart Anticounterfeiting Tags with AI-Aided Smartphone Authentication. ACS Applied Materials & Interfaces 14: 25898-25906.
18. Bouabdallaoui Y, Lafhaj Z, Yim P, Ducoulombier L, Bennadji B (2021) Predictive maintenance in building facilities: A machine learning-based approach. Sensors 21: 1044.
19. Dalzochio J, Kunst R, Pignaton E, Binotto A, Sanyal S, et al. (2020) Machine learning and reasoning for predictive maintenance in Industry 4.0: Current status and challenges. Computers in Industry 123: 103298.
20. Farchi F, Farchi C, Touzi B, Mabrouki C (2023) A comparative study on AI-based algorithms for cost prediction in pharmaceutical transport logistics. Acadlore Trans Mach Learn 2: 129-141.
21. Hasani N, Morris MA, Rahmim A, Summers RM, Jones E, et al. (2022) Trustworthy artificial intelligence in medical imaging. PET clinics 17: 1-12.
22. Baryannis G, Validi S, Dani S, Antoniou G (2019) Supply chain risk management and artificial intelligence: state of the art and future research directions. International Journal of Production Research 57: 2179-2202.
23. Alevizos V, Georgousis I, Simasiku A, Karypidou S, Messinis A (2023) Evaluating the Inclusiveness of Artificial Intelligence Software in Enhancing Project Management Efficiency--A Review. arXiv preprint arXiv:2311.11159.
24. Tomasello L (2019) Neural machine translation and artificial intelligence: what is left for the human translator? Università degli Studi di Padova https://core.ac.uk/download/pdf/189853844.pdf.
25. Hacker P (2021) A legal framework for AI training data - from first principles to the Artificial Intelligence Act. Law Innovation and Technology 13: 257-301.
26. Whang SE, Roh Y, Song H, Lee JG (2023) Data collection and quality challenges in deep learning: A data-centric ai perspective. The VLDB Journal 32: 791-813.
27. Amann J, Blasimme A, Vayena E, Frey D, Madai VI, et al. (2020) Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. BMC medical informatics and decision making 20: 1-9.
28. Bodimani M (2024) Assessing the Impact of Transparent AI Systems in Enhancing User Trust and Privacy. Journal of Science & Technology 5: 50-67.
29. ISO/IEC 27013:20219(en), Information security, cybersecurity and privacy protection - Guidance on the integrated implementation of ISO/IEC 27001 and ISO/IEC 20000-1. ISO https://www.iso.org/obp/ui/#iso:std:iso-iec:27013:en.
30. ISO/IEC 27005:2022(en), Information security, cybersecurity and privacy protection -Guidance on managing information security risks. ISO https://www.iso.org/obp/ui/#iso:std:iso-iec:27005:en.
31. ISO/IEC 27001:2022(en), Information security, cybersecurity and privacy protection -Information security management systems - Requirements IS0.
32. Niazi SK (2023) The coming of age of ai/ml in drug discovery, development, clinical testing, and manufacturing: The FDA perspectives. Drug Design Development and Therapy 2691-2725.
33. Farchi F, Farchi C, Touzi B, Mabrouki C (2023) A Comparative Study on AI-Based Algorithms for Cost Prediction in Pharmaceutical Transport Logistics. Acadlore Trans Mach Learn 2: 129-141.
34. Norori N, Hu Q, Aellen FM, Faraci FD, Tzovara A (2021) Addressing bias in big data and AI for health care: A call for open science. Patterns 2.
35. Challen R, Denny J, Pitt M, Gompels L, Edwards T, et al. (2019) Artificial intelligence, bias and clinical safety. BMJ quality & safety 28: 231-237.
36. Noseworthy PA, Attia ZI, Brewer LC, Hayes SN, Yao X, et al. (2020) Assessing and mitigating bias in medical artificial intelligence: the effects of race and ethnicity on a deep learning model for ECG analysis. Circulation: Arrhythmia and Electrophysiology 13: e007988.
37. Price WN, Cohen IG (2019) Privacy in the age of medical big data. Nature medicine 25: 37-43.
38. Vollmer S, Mateen BA, Bohner G, Király FJ, Ghani R, et al. (2020) Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness. BMJ 368.
39. Tangi L, van Noordt C, Rodriguez Müller AP (2023) The challenges of AI implementation in the public sector. An in-depth case studies analysis. In Proceedings of the 24th annual international conference on digital government research 414-422.
40. (2023) IEEE Introduces New Program for Free Access to AI Ethics and Governance Standards. IEEE SA https://standards.ieee.org/news/get-program-ai-ethics/.
41. Khalid N, Qayyum A, Bilal M, Al-Fuqaha A, Qadir J (2023) Privacy-preserving artificial intelligence in healthcare: Techniques and applications. Computers in Biology and Medicine 106848.
42. Eckhardt S, Knaeble M, Bucher A, Staehelin D, Dolata M, et al. (2023) Garbage In, Garbage Out: Mitigating Human Biases in Data Entry by Means of Artificial Intelligence. In IFIP Conference on Human-Computer Interaction 27-48.
43. Hanson B, Stall S, Cutcher-Gershenfeld J, Vrouwenvelder K, Wirz C, et al. (2023) Garbage in, garbage out: mitigating risks and maximizing benefits of AI in research. Nature 623: 28-31.
44. Teno JM (2023) Garbage in, garbage out-words of caution on big data and machine learning in medical practice. In JAMA Health Forum 4: e230397-e230397.
45. Hyde SJ, Bachura E, Harrison JS (2023) Garbage in, garbage out: A theory-driven approach to improve data handling in supervised machine learning. In Methods to Improve Our Field 101-132.
46. Natasha Sharma (2023) Understanding and Applying F1 Score: AI Evaluation Essentials with Hands-On Coding

Example. Arize.com https://arize.com/blog-course/f1-score/#:~:text=F1%20score%20is%20a%20measure,can%20be%20modified%20into%20F0.

47. (2002) General Principles of Software Validation. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation.
48. Rath KC, Khang A, Rath SK, Satapathy N, Satapathy SK, et al. (2024) Artificial Intelligence (AI)-Enabled Technology in Medicine-Advancing Holistic Healthcare Monitoring and Control Systems. In Computer Vision and AI-Integrated IoT Technologies in the Medical Ecosystem 87-108.
49. Dave Pearson (2021) AI biopsy dilemma: Wolf or husky, equity or bias? Healthexec.com https://healthexec.com/topics/precision-medicine/ai-biopsy-dilemma-wolf-or-husky-equity-or-bias.
50. Mark Humphery-Jenner (2024) Google's $90 Billion AI disaster. substack.com https://financemark.substack.com/p/googles-90-billion-ai-disaster.
51. Dan Milmo, Alex Hern (2024) We definitely messed up': why did Google AI tool make offensive historical images? The Guardian https://www.theguardian.com/technology/2024/mar/08/we-definitely-messed-up-why-did-google-ai-tool-make-offensive-historical-images.
52. Jeffrey Dastin (2018) Insight - Amazon scraps secret AI recruiting tool that showed bias against women | Reuters https://www.reuters.com/article/idUSKCN1MK0AG/.